We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -44.77%. The profit margin, also known as the revenue ratio or gross profit ratio ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to Buy. Analyst Price Forecast Suggests 518.18% Upside As of December 23, 2024, ...

Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered ...

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.

In this article, we are going to take a look at where Sana Biotechnology, Inc. (NASDAQ:SANA) stands against the other smid-cap stocks. As the name suggests, smid-cap stocks have a valuation ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...